Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowAbbott Laboratories (ABT) is set to report its second-quarter earnings on July 16. In Q1, the company's medical device revenue reached approximately $5.5 billion, contributing about 50% of total sales. The FreeStyle Libre platform alone generated roughly $2 billion in sales, with over 7 million users globally. The cardiovascular segment also showed growth, with $578 million in revenue. These figures highlight Abbott's diverse business structure and position in the medical device market, which could impact investor decisions leading up to the earnings announcement.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
- Adeptus Biotechnologies Stock Rating Maintained by BTIG
- Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
- Abbott Labs (ABT) stock price target cut to $120 by Benchmark
- Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
- Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
S&P 500 and Nasdaq Rise as AI Stocks Rebound Before Earnings
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18